WaveMan · Form 4
Schilke Tobin insider trades
> Search tickers & screens ⌘K
LIVE

Schilke Tobin insider trades

Schilke Tobin has filed 35 Form 4s with the SEC that we hold, for RVNC (CFO) and Crinetics Pharmaceuticals, Inc. (CRNX) (Chief Financial & Infra. Ofcr.). Across all of them we count 0 purchases worth $0 and 15 sales worth $2.3M reported on Form 4. In the last 12 months: 0 purchases ($0) and 1 sale ($266.3K). The largest single trade was a sale of 21,401 shares of RVNC worth $739.4K, dated 2023-05-15. The first filing on our record is dated 2021-07-02 and the latest 2026-09-01.

RVNC

CFO · 30 filings · 14 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-01-09S, sale reported on Form 41,701$42.5K2023-01-10
2023-01-09S, sale reported on Form 41,000$28.0K2023-01-10
2023-01-09S, sale reported on Form 41,000$30.0K2023-01-10
2023-01-20S, sale reported on Form 41,000$31.0K2023-01-23
2023-02-01S, sale reported on Form 43,201$110.8K2023-02-02
2023-03-01S, sale reported on Form 43,201$107.2K2023-03-02
2023-03-09S, sale reported on Form 418,517$585.0K2023-03-09
2023-04-03S, sale reported on Form 43,201$102.9K2023-04-04
2023-05-01S, sale reported on Form 43,201$101.5K2023-05-02
2023-05-15S, sale reported on Form 421,401$739.4K2023-05-16
2023-06-01S, sale reported on Form 42,701$82.6K2023-06-05
2023-06-02S, sale reported on Form 4500$15.5K2023-06-05
2023-07-03S, sale reported on Form 41,701$42.6K2023-07-05
2024-03-18S, sale reported on Form 49,361$47.2K2024-03-19

Crinetics Pharmaceuticals, Inc. (CRNX)

Chief Financial & Infra. Ofcr. · 5 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2026-03-03S, sale reported on Form 46,713$266.3K2026-03-04
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1678984) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms